You’re so silly.
Go back and read the phase 2 small cohort readouts and decide for yourself that this is a treatment that shows a small improvement on top of current standard treatment. This is a high risk drug which marginally improves the patients condition, thus the “may” in the companies statement.
The market has spoken so don’t point the finger at me!
Anyway I’m always happy to be corrected, as I’d like to be a believer too!
Ann: Dimerix Completes $20M Placement, page-63
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35000 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 83901 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |